Outlook Therapeutics (OTLK) Announces Financial Earnings Results For Third Quarter Fiscal Year 2025 And Provides Corporate Update

Outlook Therapeutics, Inc. (OTLK) today announced its financial results for the recent quarter, revealing a diluted earnings per share (EPS) of -$0.55, which fell short of analysts’ expectations by $0.20. The company’s EPS estimate was projected at -$0.35, highlighting a significant miss in performance. As Outlook Therapeutics continues to navigate its financial landscape, investors will be keenly watching for insights into the factors contributing to this shortfall.

Key Highlights:

• First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in Europe.
• ONS-5010/LYTENAVA™ (bevacizumab-vikg) PDUFA goal date set for August 27, 2025, in the U.S.
• Reported a net loss of $20.2 million for Q3 FY2025, with $1.5 million in revenue from initial sales in Germany and the UK.
• Adjusted net loss for Q3 FY2025 was $15.8 million, an improvement from $19.2 million in Q3 FY2024.
• Cash and cash equivalents as of June 30, 2025, were $8.9 million.
• Strategic collaboration with Cencora to support global commercial launch of LYTENAVA™.

Outlook Therapeutics, Inc. reported its financial results for the third quarter of fiscal year 2025, highlighting the commencement of commercial sales of LYTENAVA™ in Europe, specifically in Germany and the UK. CEO Bob Jahr stated, “With the first commercial sales of LYTENAVA™ (bevacizumab gamma) in Europe for the treatment of wet AMD, the transformation of Outlook Therapeutics into a commercial company has begun.” The company is actively preparing for potential U.S. FDA approval of ONS-5010, which is expected to be branded as LYTENAVA™ (bevacizumab-vikg) if approved.

The financial results showed a net loss of $20.2 million for the quarter, with revenue generated from initial sales of LYTENAVA™. The adjusted net loss improved compared to the previous year, indicating progress in the company’s financial health. Outlook Therapeutics is also focused on mitigating risks associated with off-label use of repackaged bevacizumab, with ONS-5010 positioned as a safer alternative. The company’s collaboration with Cencora aims to enhance market access and distribution efficiency for LYTENAVA™, benefiting stakeholders in the healthcare ecosystem.

Outlook Therapeutics, Inc. (OTLK) has experienced a notable price surge of 13.30% over the past week, signaling a potential rebound after a challenging year where the stock plummeted by 72.52%. This recent uptick may be attributed to positive sentiment surrounding the company’s future prospects, especially given its impressive revenue growth rate of 46.19% over the past two years. However, the price-to-earnings ratio stands at a strikingly low 0.42, indicating that the market may still be skeptical about the company’s profitability and long-term viability. Despite the recent gains, the stock has only managed a modest increase of 2.90% over the past month and 4.93% over the last three months, suggesting that volatility remains a key characteristic of OTLK’s performance. Investors will be keenly watching how the company navigates its financial challenges and whether it can sustain this momentum in the coming months. As Outlook Therapeutics continues to develop its pipeline, the market’s reaction will likely hinge on upcoming announcements and financial results.

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.